Tag - VTVT

Markets

Cantor starts vTv at OW; PT $5

Cantor Fitzgerald launched coverage of vTv Therapeutics (NASDAQ:VTVT) with an “overweight” rating and 12-month price target of $5. The stock closed at 71 cents on Feb. 17. vTv is developing novel orally administered...

February 18, 2022

Developments

vTv Therapeutics azeliragon fails Phase 2 AD and T2D trial

vTv Therapeutics’ (NASDAQ:VTVT) Phase 2 trial of azeliragon in patients with Alzheimer’s disease (AD) and Type 2 diabetes (T2D) failed to meet its primary endpoint. The trial enrolled 43 patients who were randomized to...

December 16, 2020

Developments

vTv Therapeutics’ Phase 2 diabetes trial meets primary objective

vTv Therapeutics’ (NASDAQ:VTVT) Phase 2 trial of TTP399 in Type 1 diabetes (T1D) patients met its primary objective by demonstrating statistically significant improvements in HbA1c compared to placebo. The company...

February 10, 2020

Markets

Stifel cuts vTv Therapeutics to hold; PT to $1 from $12

Stifel downgraded vTv Therapeutics (NASDAQ:VTVT) to “hold” from “buy” and slashed its price target to $1 from $12 after the company reported negative top line results from its Phase 3 STEADFAST study in mild Alzheimer’s...

April 10, 2018

Markets

Roth starts coverage of 3 companies with novel approaches to AD

Roth Capital Partners initiated coverage of three companies – vtv Therapeutics (NASDAQ:VTVT), Anevex Life Sciences (NASDAQ:AVXL) and Neurotrope Biosciences (NASDAQ:NTRP) – that are developing drugs with novel...

March 9, 2018

Tag - VTVT

Cantor starts vTv at OW; PT $5

vTv Therapeutics azeliragon fails Phase 2 AD and T2D trial

vTv Therapeutics’ Phase 2 diabetes trial meets primary objective

Stifel cuts vTv Therapeutics to hold; PT to $1 from $12

Roth starts coverage of 3 companies with novel approaches to AD

General

More